Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.

O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, Dasso M, Bates GP, Difiglia M, Davidson B, Wanker EE, Marsh JL, Lima CD, Steffan JS, Thompson LM.

Cell Rep. 2013 Jul 25;4(2):362-75. doi: 10.1016/j.celrep.2013.06.034. Epub 2013 Jul 18.


CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.

Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM.

Mol Cell Neurosci. 2008 Sep;39(1):8-20. doi: 10.1016/j.mcn.2008.04.007. Epub 2008 Apr 24.


Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.

Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E.

Mol Cell Neurosci. 2008 Sep;39(1):1-7. doi: 10.1016/j.mcn.2008.04.012. Epub 2008 May 10.


Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM.

Hum Mol Genet. 2006 Jan 15;15(2):273-85. Epub 2005 Dec 5.


Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.

Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson LM.

Hum Mol Genet. 2005 Jun 1;14(11):1529-38. Epub 2005 Apr 20.


Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.

Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81. Epub 2005 Feb 16.


Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.

Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH.

Neurobiol Dis. 2003 Dec;14(3):624-36.


Autophagy regulates the processing of amino terminal huntingtin fragments.

Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson LM, Yoder J, Aronin N, DiFiglia M.

Hum Mol Genet. 2003 Dec 15;12(24):3231-44. Epub 2003 Oct 21.


A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson LM.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5. Epub 2003 May 1.


Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM.

Nature. 2001 Oct 18;413(6857):739-43.


Antisense-mediated down-regulation of the human huntingtin gene.

Boado RJ, Kazantsev A, Apostol BL, Thompson LM, Pardridge WM.

J Pharmacol Exp Ther. 2000 Oct;295(1):239-43.


Population genetics with RAPD-PCR markers: the breeding structure of Aedes aegypti in Puerto Rico.

Apostol BL, Black WC 4th, Reiter P, Miller BR.

Heredity (Edinb). 1996 Apr;76 ( Pt 4):325-34.


Regional assignment and tissue expression of twenty-three expressed sequence tags (ESTs) from human chromosome 5.

Feldblyum TV, Maglott DR, McPherson JD, Adams M, Apostol BL, Durkin AS, Wasmuth JJ, Nierman WC.

Genomics. 1996 Apr 1;33(1):128-30.


Estimation of the number of full sibling families at an oviposition site using RAPD-PCR markers: applications to the mosquito Aedes aegypti.

Apostol BL, Black WC 4th, Miller BR, Reiter P, Beaty BJ.

Theor Appl Genet. 1993 Sep;86(8):991-1000. doi: 10.1007/BF00211052.


Novel activity of a yeast ligase deletion polypeptide. Evidence for GTP-dependent tRNA splicing.

Westaway SK, Belford HG, Apostol BL, Abelson J, Greer CL.

J Biol Chem. 1993 Feb 5;268(4):2435-43.


Preferential binding of yeast tRNA ligase to pre-tRNA substrates.

Apostol BL, Greer CL.

Nucleic Acids Res. 1991 Apr 25;19(8):1853-60.


Supplemental Content

Loading ...
Support Center